Key clinical point: Treatment with omalizumab for 24 weeks reduced severity in pediatric atopic dermatitis patients.
Major finding: After 24 weeks, the adjusted mean difference in objective SCORAD index between the two groups was -6.9 in favor of omalizumab (95% CI, -12.2 to -1.5; P = .01).
Study details: A single-center, double-blind, placebo-controlled randomized clinical trial of 62 patients with childhood atopic dermatitis.
Disclosures: The study was funded by the National Institute for Health Research Efficacy and Mechanism Evaluation Programme and Guy's and St. Thomas' Charity. The authors had numerous financial disclosures, including receiving grants from the NIHR EME Programme and Guy's and St. Thomas' Charity along with active and placebo drugs from Novartis for use in the study.
Chan S et al. JAMA Pediatr. 2019 Nov 25. doi: 10.1001/jamapediatrics.2019.4476.